Potential Biomarkers for Esophageal Cancer

Overview

Journal Springerplus

Date 2016 Apr 28

PMID 27119071

Citations 26

Authors

Cheng Tan

Xia Qian

Zhifeng Guan

Baixia Yang

Yangyang Ge

Feng Wang

Jing Cai

Affiliations

Soon will be listed here.

Abstract

Esophageal cancer, which consist of esophageal adenocarcinoma and esophageal squamous cell carcinoma, is one of the most common malignant tumors in the world, especially in the south of Iran and China. To find and investigate the biomarkers in the initiation, development and progression of esophageal cancer will help us predict the prognosis of esophageal cancer patients and improve the curative effect and survival rate. Here, we reviewed the potential biomarkers of esophageal cancer in three aspects: Immunohistochemical markers, blood-based markers, miRNA markers and Gene expression profiling. All these biomarkers provided promising therapeutic targets for the diagnosis, treatment, and prognosis of esophageal cancer.

Citing Articles

Long non-coding RNA HOXC-AS1 promotes the malignancy by sponging miR-195-5p with ANLN in esophageal cancer.

Su Y, Kuang F, Guo H, Chen Q, Lai Y, Jing R Cytotechnology. 2025; 77(2):68.

PMID: 40012926 PMC: 11850670. DOI: 10.1007/s10616-025-00711-z.

Inhibition of Insulin-like Growth Factor 1 Receptor/Insulin Receptor Signaling by Small-Molecule Inhibitor BMS-754807 Leads to Improved Survival in Experimental Esophageal Adenocarcinoma.

Hassan M, Johnson C, Ponna S, Scofield D, Awasthi N, von Holzen U Cancers (Basel). 2024; 16(18).

PMID: 39335147 PMC: 11430189. DOI: 10.3390/cancers16183175.

Exploring Potential Biomarkers in Oesophageal Cancer: A Comprehensive Analysis.

Romanowicz A, Lukaszewicz-Zajac M, Mroczko B Int J Mol Sci. 2024; 25(8).

PMID: 38673838 PMC: 11050399. DOI: 10.3390/ijms25084253.

The role of microbiota in esophageal squamous cell carcinoma: A review of the literature.

Chiang H, Hughes M, Chang W Thorac Cancer. 2023; 14(28):2821-2829.

PMID: 37675608 PMC: 10542467. DOI: 10.1111/1759-7714.15096.

Current Status and Future Prospects for Esophageal Cancer.

Sheikh M, Roshandel G, McCormack V, Malekzadeh R Cancers (Basel). 2023; 15(3).

PMID: 36765722 PMC: 9913274. DOI: 10.3390/cancers15030765.

References

Lesnikova I, Lidang M, Hamilton-Dutoit S, Koch J . HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. APMIS. 2009; 117(10):737-45. DOI: 10.1111/j.1600-0463.2009.02531.x. View

Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G . HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus. 2006; 19(4):224-31. DOI: 10.1111/j.1442-2050.2006.00570.x. View

Uemura N, Kondo T . Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer. World J Gastrointest Pathophysiol. 2014; 5(3):322-34. PMC: 4133529. DOI: 10.4291/wjgp.v5.i3.322. View

Skacel M, Petras R, Rybicki L, Gramlich T, Richter J, Falk G . p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol. 2002; 97(10):2508-13. DOI: 10.1111/j.1572-0241.2002.06032.x. View

Kilic A, Schuchert M, Luketich J, Landreneau R, Lokshin A, Bigbee W . Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum. J Thorac Cardiovasc Surg. 2008; 136(1):199-204. DOI: 10.1016/j.jtcvs.2008.01.012. View

Sudo T, Mimori K, Nagahara H, Utsunomiya T, Fujita H, Tanaka Y . Identification of EGFR mutations in esophageal cancer. Eur J Surg Oncol. 2006; 33(1):44-8. DOI: 10.1016/j.ejso.2006.10.034. View

Quackenbush J . Microarray analysis and tumor classification. N Engl J Med. 2006; 354(23):2463-72. DOI: 10.1056/NEJMra042342. View

Fitzgerald R, di Pietro M, Ragunath K, Ang Y, Kang J, Watson P . British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2013; 63(1):7-42. DOI: 10.1136/gutjnl-2013-305372. View

DiMaio M, Kwok S, Montgomery K, Lowe A, Pai R . Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping. Hum Pathol. 2012; 43(11):1799-807. PMC: 3465493. DOI: 10.1016/j.humpath.2012.03.019. View

10.

Xu Y, Peng Y, Chen B, Wu Z, Wu J, Shen J . Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol. 2013; 109(1):36-45. PMC: 3887578. DOI: 10.1038/ajg.2013.384. View

11.

Huang Y, Liu J, Deatherage D, Luo J, Mutch D, Goodfellow P . Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 2009; 69(23):9038-46. PMC: 2789184. DOI: 10.1158/0008-5472.CAN-09-1499. View

12.

Zhang H, Xu L, Li E . A family of pleiotropically acting microRNAs in cancer progression, miR-200: potential cancer therapeutic targets. Curr Pharm Des. 2013; 20(11):1896-903. DOI: 10.2174/13816128113199990519. View

13.

Glickman J, Yang A, Shahsafaei A, McKeon F, Odze R . Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol. 2001; 32(11):1157-65. DOI: 10.1053/hupa.2001.28951. View

14.

Shimada H, Nakashima K, Ochiai T, Nabeya Y, Takiguchi M, Nomura F . Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol. 2004; 26(1):77-86. View

15.

Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura R, Ruschoff J . Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009; 132(4):539-48. DOI: 10.1309/AJCPV2I0HGPMGBSQ. View

16.

Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y . c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003; 57(5):1323-7. DOI: 10.1016/s0360-3016(03)00782-x. View

17.

Rice T, Zuccaro Jr G, Adelstein D, Rybicki L, Blackstone E, Goldblum J . Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg. 1998; 65(3):787-92. DOI: 10.1016/s0003-4975(97)01387-8. View

18.

Luthra R, Singh R, Luthra M, Li Y, Hannah C, Romans A . MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008; 27(52):6667-78. DOI: 10.1038/onc.2008.256. View

19.

Zhang H, Li M, Han Y, Hong L, Gong T, Sun L . Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2009; 55(9):2545-51. DOI: 10.1007/s10620-009-1051-6. View

20.

Vervoort S, van Boxtel R, Coffer P . The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe?. Oncogene. 2012; 32(29):3397-409. DOI: 10.1038/onc.2012.506. View